Nemtabrutinib
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancies
Conditions
Hematological Malignancies
Trial Timeline
Jun 9, 2022 → Apr 30, 2027
NCT ID
NCT05347225About Nemtabrutinib
Nemtabrutinib is a phase 1 stage product being developed by Merck for Hematological Malignancies. The current trial status is active. This product is registered under clinical trial identifier NCT05347225. Target conditions include Hematological Malignancies.
What happened to similar drugs?
0 of 1 similar drugs in Hematological Malignancies were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06442436 | Phase 1 | Recruiting |
| NCT06772818 | Phase 1 | Completed |
| NCT06586671 | Phase 1 | Completed |
| NCT06772805 | Phase 1 | Completed |
| NCT05673460 | Phase 1 | Completed |
| NCT05347225 | Phase 1 | Active |
| NCT04728893 | Phase 2 | Recruiting |
| NCT03162536 | Phase 1/2 | Active |
Competing Products
20 competing products in Hematological Malignancies